Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new ...
GlobalData on MSN
Natera demonstrates MRD test benefit in colorectal cancer patients
Ahead of the study's publication, the data was shared at the 2026 European Society for Medical Oncology Gastrointestinal ...
Natera, Inc. , a global leader in cell-free DNA and precision medicine, today announced the publication of new data in JAMA Oncology, evaluating the utility of Signatera, its personalized molecular ...
GlobalData on MSN
Natera, Aveta Biomics collaborate on head and neck cancer trial
Around 826 participants will be recruited across Australia, Asia-Pacific, Europe and North America.
Natera NTRA recently announced a partnership with Aveta Biomics to support AVTA 30-01, a global Phase 3 registrational trial of its oral immunotherapy, APG-157, in patients with locally advanced head ...
Reports demonstrates that whole-brain Single Photon Emission Computed Tomography (SPECT) imaging, combined with advanced machine learning techniques, can successfully differentiate individuals ...
Natera’s latest earnings call struck an emphatically upbeat tone, with management highlighting broad-based momentum across oncology and women’s health. Revenue, volumes, and pricing all moved higher, ...
Despite fears of an innovation slowdown, stoked by funding cuts and FDA personnel shakeups, the agency approved 17 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results